Cardiovascular Systems Inc.
| NASDAQ: CSII | Healthcare / Medical Devices & Instruments / USA |
| 19.86 | 0 | 0.00 | Vol 353.86K | 1Y Perf -12.12% |
| Mar 31st, 2023 16:00 DELAYED |
| BID | 19.85 | ASK | 19.87 | ||
| Open | 19.87 | Previous Close | 19.86 | ||
| Pre-Market | - | After-Market | 19.54 | ||
| - - | -0.32 -1.61% |
| Target Price | 21.20 | Analyst Rating | Moderate Sell 3.60 | |
| Potential % | 6.75 | Finscreener Ranking | ★★★+ 50.22 | |
| Insiders Trans % 3/6/12 mo. | 100/100/100 | Value Ranking | ★★★★ 56.79 | |
| Insiders Value % 3/6/12 mo. | 100/100/100 | Growth Ranking | ★★ 46.47 | |
| Insiders Shares Cnt. % 3/6/12 mo. | 100/100/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 67.81 | Earnings Rating | Strong Buy | |
| Market Cap | 838.05M | Earnings Date | 3rd May 2023 | |
| Alpha | -0.01 | Standard Deviation | 0.13 | |
| Beta | 0.94 |
Today's Price Range 19.8519.91 | 52W Range 12.2623.47 | 5 Year PE Ratio Range -1 300.00912.30 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 0.10% | ||
| 1 Month | 0.46% | ||
| 3 Months | 45.81% | ||
| 6 Months | 43.29% | ||
| 1 Year | -12.12% | ||
| 3 Years | -43.80% | ||
| 5 Years | -9.44% | ||
| 10 Years | -4.01% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -4.50 | |||
ROE last 12 Months | -16.75 | |||
ROA (5Y Avg) | -2.30 | |||
ROA last 12 Months | -13.12 | |||
ROC (5Y Avg) | -1.77 | |||
ROC last 12 Months | -14.15 | |||
Return on invested Capital Q | -4.07 | |||
Return on invested Capital Y | -12.91 | |||
Assets Turnover | 0.60 | |||
Receivables Turnover | 4.90 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -14.50 | ||||
| 2.48 | ||||
| 3.27 | ||||
| 289.80 | ||||
| -28.50 | ||||
| -0.69 | ||||
| 2.65 | ||||
| 5.78 | ||||
| 477.86M | ||||
| Forward PE | -40.53 | |||
| PEG | -0.46 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 5.00 | ||||
| 6.20 | ||||
| 0.08 | ||||
| 0.09 | ||||
| -22.80 | ||||
| Leverage Ratio | 1.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 72.30 | ||||
| -15.60 | ||||
| -13.50 | ||||
| -3.30 | ||||
| -16.74 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 178.39M | ||||
| 4.26 | ||||
| -5.83 | ||||
| 4.29 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.15 | -0.20 | -33.33 |
| Q01 2023 | -0.24 | -0.27 | -12.50 |
| Q04 2022 | -0.22 | -0.25 | -13.64 |
| Q03 2022 | -0.28 | -0.25 | 10.71 |
| Q02 2022 | -0.14 | -0.23 | -64.29 |
| Q01 2022 | -0.10 | -0.22 | -120.00 |
| Q04 2021 | -0.17 | -0.14 | 17.65 |
| Q03 2021 | -0.10 | -0.15 | -50.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2022 QR | -0.15 | 6.25 | Positive |
| 3/2023 QR | -0.15 | 0.00 | - |
| 6/2023 FY | -0.67 | 0.00 | - |
| 6/2024 FY | -0.49 | 2.00 | Positive |
| Next Report Date | 3rd May 2023 |
| Estimated EPS Next Report | -0.15 |
| Estimates Count | 4 |
| EPS Growth Next 5 Years % | 31.70 |
| Volume Overview | |
|---|---|
| Volume | 353.86K |
| Shares Outstanding | 42.20K |
| Shares Float | 26.44M |
| Trades Count | 2.86K |
| Dollar Volume | 7.03M |
| Avg. Volume | 642.00K |
| Avg. Weekly Volume | 388.18K |
| Avg. Monthly Volume | 739.19K |
| Avg. Quarterly Volume | 798.65K |
Cardiovascular Systems Inc. (NASDAQ: CSII) stock closed at 19.86 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 353.86K shares and market capitalization of 838.05M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 779 people. Cardiovascular Systems Inc. CEO is Scott R. Ward.
The one-year performance of Cardiovascular Systems Inc. stock is -12.12%, while year-to-date (YTD) performance is 45.81%. CSII stock has a five-year performance of -9.44%. Its 52-week range is between 12.255 and 23.47, which gives CSII stock a 52-week price range ratio of 67.81%
Cardiovascular Systems Inc. currently has a PE ratio of -14.50, a price-to-book (PB) ratio of 2.48, a price-to-sale (PS) ratio of 3.27, a price to cashflow ratio of 289.80, a PEG ratio of 2.32, a ROA of -13.12%, a ROC of -14.15% and a ROE of -16.75%. The company’s profit margin is -16.74%, its EBITDA margin is -13.50%, and its revenue ttm is $178.39 Million , which makes it $4.26 revenue per share.
Of the last four earnings reports from Cardiovascular Systems Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.15 for the next earnings report. Cardiovascular Systems Inc.’s next earnings report date is 03rd May 2023.
The consensus rating of Wall Street analysts for Cardiovascular Systems Inc. is Moderate Sell (3.6), with a target price of $21.2, which is +6.75% compared to the current price. The earnings rating for Cardiovascular Systems Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cardiovascular Systems Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Cardiovascular Systems Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 9.65, ATR14 : 0.15, CCI20 : 124.04, Chaikin Money Flow : 0.30, MACD : 0.39, Money Flow Index : 70.42, ROC : 0.51, RSI : 75.45, STOCH (14,3) : 81.13, STOCH RSI : 0.47, UO : 51.41, Williams %R : -18.87), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cardiovascular Systems Inc. in the last 12-months were: Jeffrey S. Points (Buy at a value of $43 496), Martha Goldberg Aronson (Option Excercise at a value of $0), Scott R. Ward (Buy at a value of $43 467)
Cardiovascular Systems Inc.
Cardiovascular Systems Inc is a medical technology company focused on patients with peripheral and coronary artery diseases. Its peripheral artery disease systems are catheter-based platforms used to treat plaque in leg arteries above and below the knee. The firm's orbital atherectomy systems are used in peripheral and coronary commercial applications. Its OAS products include the Diamondback 360 Peripheral and Stealth 360 systems. Sales of Peripheral OAS contribute the majority of revenue. Cardiovascular systems generates the vast majority of its revenue in the United States.
CEO: Scott R. Ward
Telephone: +1 651 259-1600
Address: 1225 Old Highway 8 Northwest, St. Paul 55112-6416, MN, US
Number of employees: 779
